TY - JOUR
T1 - New positron emission tomography derived parameters as predictive factors for recurrence in resected stage i non-small cell lung cancer
AU - Melloni, G.
AU - Gajate, A. M S
AU - Sestini, S.
AU - Gallivanone, F.
AU - Bandiera, A.
AU - Landoni, C.
AU - Muriana, P.
AU - Gianolli, L.
AU - Zannini, P.
PY - 2013/11
Y1 - 2013/11
N2 - Background The recurrence rate for stage I non-small cell lung cancer is high, with 20-40% of patients that relapse after surgery. The aim of this study was to evaluate new F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) derived parameters, such as standardized uptake value index (SUV index), metabolic tumor volume (MTV) and total lesion glycolysis (TLG), as predictive factors for recurrence in resected stage I non-small cell lung cancer. Methods We retrospectively reviewed 99 resected stage I non-small cell lung cancer patients that were grouped by SUVindex, TLG and MTV above or below their median value. Disease free survival was evaluated as primary end point. Results The 5-year overall survival and the 5-year disease free survival rates were 62% and 73%, respectively. The median SUV index, MTL and TLG were 2.73, 2.95 and 9.61, respectively. Patients with low SUVindex, MTV and TLG were more likely to have smaller tumors (p ≤ 0.001). Univariate analysis demonstrated that SUVindex (p = 0.027), MTV (p = 0.014) and TLG (p = 0.006) were significantly related to recurrence showing a better predictive performance than SUVmax (p = 0.031). The 5-year disease free survival rates in patients with low and high SUVindex, MTV and TLG were 84% and 59%, 86% and 62% and 88% and 60%, respectively. The multivariate analysis showed that only TLG was an independent prognostic factor (p = 0.014) with a hazard ratio of 4.782. Conclusion Of the three PET-derived parameters evaluated, TLG seems to be the most accurate in stratifying surgically treated stage I non-small cell lung cancer patients according to their risk of recurrence.
AB - Background The recurrence rate for stage I non-small cell lung cancer is high, with 20-40% of patients that relapse after surgery. The aim of this study was to evaluate new F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) derived parameters, such as standardized uptake value index (SUV index), metabolic tumor volume (MTV) and total lesion glycolysis (TLG), as predictive factors for recurrence in resected stage I non-small cell lung cancer. Methods We retrospectively reviewed 99 resected stage I non-small cell lung cancer patients that were grouped by SUVindex, TLG and MTV above or below their median value. Disease free survival was evaluated as primary end point. Results The 5-year overall survival and the 5-year disease free survival rates were 62% and 73%, respectively. The median SUV index, MTL and TLG were 2.73, 2.95 and 9.61, respectively. Patients with low SUVindex, MTV and TLG were more likely to have smaller tumors (p ≤ 0.001). Univariate analysis demonstrated that SUVindex (p = 0.027), MTV (p = 0.014) and TLG (p = 0.006) were significantly related to recurrence showing a better predictive performance than SUVmax (p = 0.031). The 5-year disease free survival rates in patients with low and high SUVindex, MTV and TLG were 84% and 59%, 86% and 62% and 88% and 60%, respectively. The multivariate analysis showed that only TLG was an independent prognostic factor (p = 0.014) with a hazard ratio of 4.782. Conclusion Of the three PET-derived parameters evaluated, TLG seems to be the most accurate in stratifying surgically treated stage I non-small cell lung cancer patients according to their risk of recurrence.
KW - Imaging
KW - Non-small cell lung cancer
KW - PET
KW - Prognosis
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=84885427344&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885427344&partnerID=8YFLogxK
U2 - 10.1016/j.ejso.2013.07.092
DO - 10.1016/j.ejso.2013.07.092
M3 - Article
C2 - 23948705
AN - SCOPUS:84885427344
VL - 39
SP - 1254
EP - 1261
JO - European Journal of Surgical Oncology
JF - European Journal of Surgical Oncology
SN - 0748-7983
IS - 11
ER -